Paper39338387
Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis.
Chakrabartty A. Pharmaceuticals (Basel), 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis. Papers, record 39338387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39338387
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P41 GM103311 | NIGMS NIH HHS | United States | P41GM103311 | PubMed | NIH RePORTER |
| Sponsored Research Agreement | Prothena Biosciences | PubMed | PubMed |
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28218749 | Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90. | Nat Struct Mol Biol | 2017 | https://conductscience.org/library/papers/28218749 | PubMed |
| 2 | 22244854 | The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. | J Mol Biol | 2012 | https://conductscience.org/library/papers/22244854 | PubMed |
| 3 | 27122057 | Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. | Sci Rep | 2016 | https://conductscience.org/library/papers/27122057 | PubMed |
| 4 | 37285532 | Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37285532 | PubMed |
| 5 | 1390650 | Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. | Biochemistry | 1992 | https://conductscience.org/library/papers/1390650 | PubMed |
| 6 | 16185074 | Cys114-linked dimers of transthyretin are compatible with amyloid formation. | Biochemistry | 2005 | https://conductscience.org/library/papers/16185074 | PubMed |
| 7 | 34035264 | A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. | Nat Commun | 2021 | https://conductscience.org/library/papers/34035264 | PubMed |
| 8 | 36795354 | RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis. | BioDrugs | 2023 | https://conductscience.org/library/papers/36795354 | PubMed |
| 9 | 10077645 | Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. | Proc Natl Acad Sci U S A | 1999 | https://conductscience.org/library/papers/10077645 | PubMed |
| 10 | 30145929 | Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30145929 | PubMed |
| 11 | 24648510 | Physiological IgM class catalytic antibodies selective for transthyretin amyloid. | J Biol Chem | 2014 | https://conductscience.org/library/papers/24648510 | PubMed |
| 12 | 32929754 | Systemic amyloidosis from A (AA) to T (ATTR): a review. | J Intern Med | 2021 | https://conductscience.org/library/papers/32929754 | PubMed |
| 13 | 4968450 | Influence of age and sex on prealbumin levels. | Clin Chim Acta | 1968 | https://conductscience.org/library/papers/4968450 | PubMed |
| 14 | 36399070 | Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy. | Amyloid | 2023 | https://conductscience.org/library/papers/36399070 | PubMed |
| 15 | 22378262 | Tafamidis. | Nat Rev Drug Discov | 2012 | https://conductscience.org/library/papers/22378262 | PubMed |
| 16 | 24164623 | Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. | Rejuvenation Res | 2014 | https://conductscience.org/library/papers/24164623 | PubMed |
| 17 | 37111614 | Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37111614 | PubMed |
| 18 | 8639594 | The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. | Biochemistry | 1996 | https://conductscience.org/library/papers/8639594 | PubMed |
| 19 | 9789022 | Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9789022 | PubMed |
| 20 | 279930 | Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. | Proc Natl Acad Sci U S A | 1978 | https://conductscience.org/library/papers/279930 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939656 | Transthyretin Amyloidosis: From Mechanisms to Treatment. | Biomolecules | 2026 | https://conductscience.org/library/papers/42939656 | PubMed |
| 42380466 | The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivity. | NPJ Drug Discov | 2025 | https://conductscience.org/library/papers/42380466 | PubMed |
| 42228252 | Context-of-use-Guided Development and Validation of a Transthyretin Immunoassay: A Framework for Biomarker Assay Design. | AAPS J | 2026 | https://conductscience.org/library/papers/42228252 | PubMed |
| 41801500 | Transthyretin amyloid depletion therapy: lessons from the phase 2 trial of coramitug. | Heart Fail Rev | 2026 | https://conductscience.org/library/papers/41801500 | PubMed |
| 41309103 | [Diagnosis of Amyloidosis in Hand and Plastic Surgery Patients: Optimal Tissue Selection and Examination Methods for Early Detection]. | Handchir Mikrochir Plast Chir | 2026 | https://conductscience.org/library/papers/41309103 | PubMed |
| 40649158 | Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. | J Clin Med | 2025 | https://conductscience.org/library/papers/40649158 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TTR | 7276 | PubTator's text mining | https://conductscience.org/library/genes/7276 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39338387
GET https://conductscience.org/api/papers/v1/39338387/references?page=2